Can pressurized oxygen boost stem cell transplants for myeloma?
NCT ID NCT04862676
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-phase study tested whether repeated hyperbaric oxygen therapy is safe for multiple myeloma patients who are about to receive high-dose chemotherapy and a stem cell transplant. Twenty-nine participants were exposed to 100% oxygen at 2.5 times normal atmospheric pressure for 90-minute sessions. The main goal was to check for serious side effects within 24 hours and longer-term effects up to 100 days after transplant.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
hyperbaric oxygen
What this could lead to
If it works, this could point toward a way to make stem cell transplants safer and more effective for multiple myeloma patients.
What could go wrong
This is a very early, small pilot study with only 29 participants. It only looked at safety, not whether hyperbaric oxygen actually helps treat the cancer. There are also risks like seizures or lung injury from the high-pressure oxygen.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
James P. Wilmot Cancer Center at University of Rochester Medical Center
Rochester, New York, 14642-0001, United States